Mudit Gupta

Mudit Gupta

Director Director DIN 07826119
DIN 07826119 First appointment Jul 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Jul 2017
Shareholding value •••• Premium profile

About Mudit Gupta

Data last updated:

Mudit Gupta was a Director at Tirupati Medilines Private Limited (2020–2025) and Director at Labhya Foundation (2017–2018). The companies operate in Pharma and Education.

DIN 07826119
Primary Designation Director
Industry Pharma
First Appointment 21 Jul 2017

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Tirupati Medilines Private Limited U51397DL2011PTC226590
Director28 Oct 20202011₹9.37 Cr (FY 2025)Active
Labhya Foundation U74999DL2017NPL321048
Director21 Jul 20172017₹11.02 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Tirupati Medilines Private Limited
Labhya Foundation
Premium access

Shareholding and investment profile for Mudit Gupta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mudit Gupta

Mudit Gupta was first appointed on 21 Jul 2017 as Director at Labhya Foundation. The most recent appointment on record is 28 Oct 2020 at Tirupati Medilines Private Limited.

Mudit Gupta held 2 earlier board appointments: Tirupati Medilines Private Limited (Director, 28 Oct 2020 to 04 Jul 2025); Labhya Foundation (Director, 21 Jul 2017 to 16 May 2018).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available